Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing

被引:10
|
作者
Jaffre, Jeremy [1 ,2 ]
Aubry, Alexandra [1 ,2 ]
Maitre, Thomas [1 ]
Morel, Florence [1 ,2 ]
Brossier, Florence [1 ,2 ]
Robert, Jerome [1 ,2 ]
Sougakoff, Wladimir [1 ,2 ]
Veziris, Nicolas [1 ,2 ,3 ]
机构
[1] Sorbonne Univ, Grp Hosp Univ, Hop Pitie Salpetriere, AP HP,Ctr Natl Reference Mycobacteries & Resistan, Paris, France
[2] Sorbonne Univ, INSERM, Cimi Paris, Ctr Immunol & Malad Infect,U1135, Paris, France
[3] Sorbonne Univ, Grp Hosp Univ, Hop St Antoine, AP HP, Paris, France
关键词
drug susceptibility testing; Mycobacterium avium complex; SLOMYCO Sensititre; Mueller Hinton; clarithromycin; amikacin; IN-VITRO ACTIVITY; RANDOMIZED-TRIAL; LUNG-DISEASE; CLARITHROMYCIN; THERAPY; COMBINATION; ETHAMBUTOL; RIFABUTIN; REGIMENS; AMIKACIN;
D O I
10.3389/fmicb.2020.00081
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Clinical and Laboratory Standards Institute recommends the use of Mueller Hinton (MH) medium to perform drug susceptibility testing (DST) of Mycobacterium avium complex (MAC) using the microdilution method. For MAC, there has been no study on the impact of media on the determination of minimum inhibitory concentrations (MICs) of antibiotics other than clarithromycin. This study aimed at determining the impact of two media used for DST of MAC and at augmenting the number of pertinent MICs for MAC species encountered in clinical practice. MICs of antibiotics used for the treatment of MAC infections were determined for 158 clinical MAC isolates (80 M. avium, 40 M. intracellulare, 35 M. chimaera, two M. yongonense and one M. timonense) in MH and 7H9 broths using the SLOMYCO Sensititre(TM) system (TREK Diagnostic Systems, East Grinstead, United Kingdom). The modal MICs determined in both media were the same for linezolid, moxifloxacin, rifabutin and amikacin but not for clarithromycin, rifampin and ethambutol. The kappa test for MICs converted to susceptibility categories showed an excellent agreement for clarithromycin, a moderate agreement for linezolid and a weak agreement for moxifloxacin and amikacin. For amikacin, 7H9 allowed a better distinction (fewer intermediate strains) of wild-type populations than MH. Existing breakpoints for linezolid and moxifloxacin are spread through the distribution of MICs for wild-type populations. The only breakpoints that can be used rationally are those for amikacin and clarithromycin. For amikacin, 7H9 performs better than MH, whereas both media perform equally for clarithromycin. Given that testing in 7H9, as opposed to MH, allows easier MIC measurements and yields greater reproducibility, we propose the use of 7H9 medium for DST of MAC.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] The ESP culture system for drug susceptibilities of Mycobacterium avium complex
    Lui, AY
    LaBombardi, VJ
    Turett, GS
    Kislak, JW
    Nord, JA
    CLINICAL MICROBIOLOGY AND INFECTION, 2000, 6 (12) : 649 - 652
  • [32] Antimicrobial susceptibility testing of Mycobacteroides (Mycobacterium) abscessus complex, Mycolicibacterium (Mycobacterium) fortuitum, and Mycobacteroides (Mycobacterium) chelonae
    Aono, Akio
    Morimoto, Kozo
    Chikamatsu, Kinuyo
    Yamada, Hiroyuki
    Igarashi, Yuriko
    Murase, Yoshiro
    Takaki, Akiko
    Mitarai, Satoshi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2019, 25 (02) : 117 - 123
  • [33] DEVELOPMENT OF EFFECTIVE DRUG-COMBINATIONS FOR THE INHIBITION OF MULTIPLY RESISTANT MYCOBACTERIA, ESPECIALLY OF THE MYCOBACTERIUM-AVIUM COMPLEX
    SEYDEL, JK
    SCHAPER, KJ
    RUSCHGERDES, S
    CHEMOTHERAPY, 1992, 38 (03) : 159 - 168
  • [34] Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey
    van Ingen, Jakko
    Aliberti, Stefano
    Andrejak, Claire
    Chalmers, James D.
    Codecasa, Luigi R.
    Daley, Charles L.
    Hasegawa, Naoki
    Griffith, David E.
    Hoefsloot, Wouter
    Huitt, Gwen
    Jarand, Julie
    Jhun, Byung Woo
    Loebinger, Michael R.
    Marras, Theodore K.
    Morimoto, Kozo
    Polverino, Eva
    Ringshausen, Felix C.
    Santin, Miguel
    Thomson, Rachel
    Wagner, Dirk
    Wallace, Richard J.
    Winthrop, Kevin L.
    Yim, Jae-Joon
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (01) : E256 - E259
  • [35] Antimicrobial susceptibility testing and genotyping of Mycobacterium avium isolates of two tertiary tuberculosis designated hospital, China
    Wei, Guomei
    Huang, Mingxiang
    Wang, Guirong
    Huo, Fengmin
    Dong, Lingling
    Li, Yunxu
    Huang, Hairong
    INFECTION GENETICS AND EVOLUTION, 2015, 36 : 141 - 146
  • [36] Microbial sensor for drug susceptibility testing of Mycobacterium tuberculosis
    Zhang, Z. -T.
    Wang, D. -B.
    Li, C. -Y.
    Deng, J. -Y.
    Zhang, J. -B.
    Bi, L. -J.
    Zhang, X. -E.
    JOURNAL OF APPLIED MICROBIOLOGY, 2018, 124 (01) : 286 - 293
  • [37] Proficiency of drug susceptibility testing for Mycobacterium tuberculosis in Taiwan
    Jou, R.
    Chiang, C-Y.
    Yu, C-Y.
    Wu, M-H.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2009, 13 (09) : 1142 - 1147
  • [38] Comparative analysis of phenotypic and genotypic antibiotic susceptibility patterns in Mycobacterium avium complex
    Wetzstein, Nils
    Kohl, Thomas A.
    Andres, Sonke
    Schultze, Tilman G.
    Geil, Ari
    Kim, Eunhee
    Biciusca, Teodora
    Huegel, Christian
    Hogardt, Michael
    Lehn, Annette
    Vehreschild, Maria J. G. T.
    Wolf, Timo
    Niemann, Stefan
    Maurer, Florian P.
    Wichelhaus, Thomas A.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 93 : 320 - 328
  • [39] Clinical characteristics and drug susceptibility profiles of Mycobacterium abscessus complex infection at a medical school in Thailand
    Sukmongkolchai, Songkiat
    Petsong, Suthidee
    Oudomying, Nont
    Prommi, Ajala
    Payungporn, Sunchai
    Usawakidwiree, Warat
    Wongjarit, Kanphai
    Suwanpimolkul, Gompol
    Faksri, Kiatichai
    Suankratay, Chusana
    Rotcheewaphan, Suwatchareeporn
    ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2023, 22 (01)
  • [40] Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease
    van Ingen, Jakko
    Totten, Sarah E.
    Heifets, Leonid B.
    Boeree, Martin J.
    Daley, Charles L.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2012, 39 (02) : 173 - 176